Harrer DC, Dörrie J, Schaft N (2018)
Publication Type: Journal article, Review article
Publication year: 2018
Book Volume: 29
Pages Range: 547-558
Journal Issue: 5
DOI: 10.1089/hum.2017.236
Adoptive cellular therapy has evolved into a powerful force in the battle against cancer, holding promise for curative responses in patients with advanced and refractory tumors. Autologous T cells, reprogrammed to target malignant cells via the expression of a chimeric antigen receptor (CAR) represent the frontrunner in this approach. Tremendous clinical regressions have been achieved using CAR-T cells against a variety of cancers both in numerous preclinical studies and in several clinical trials, most notably against acute lymphoblastic leukemia, and resulted in a very recent United States Food and Drug Administration approval of the first CAR-T-cell therapy. In most studies CARs are transferred to conventional αβT cells. Nevertheless, transferring a CAR into different cell types, such as γδT cells, natural killer cells, natural killer T cells, and myeloid cells has yet received relatively little attention, although these cell types possess unique features that may aid in surmounting some of the hurdles CAR-T-cell therapy currently faces. This review focuses on CAR therapy using effectors beyond conventional αβT cells and discusses those strategies against the backdrop of developing a safe, powerful, and durable cancer therapy.
APA:
Harrer, D.C., Dörrie, J., & Schaft, N. (2018). Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. Human Gene Therapy, 29(5), 547-558. https://doi.org/10.1089/hum.2017.236
MLA:
Harrer, Dennis C., Jan Dörrie, and Niels Schaft. "Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race." Human Gene Therapy 29.5 (2018): 547-558.
BibTeX: Download